360 related articles for article (PubMed ID: 33411003)
1. Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study.
Zullo AR; Lee Y; Lary C; Daiello LA; Kiel DP; Berry SD
Osteoporos Int; 2021 Mar; 32(3):565-573. PubMed ID: 33411003
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Hip Fracture Despite Treatment with Bisphosphonates among Frail Older Adults.
Zullo AR; Sorial MN; Lee Y; Lary CW; Kiel DP; Berry SD
J Am Geriatr Soc; 2020 Feb; 68(2):256-260. PubMed ID: 31580488
[TBL] [Abstract][Full Text] [Related]
3. Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.
Zullo AR; Zhang T; Lee Y; McConeghy KW; Daiello LA; Kiel DP; Mor V; Berry SD
J Am Geriatr Soc; 2019 Apr; 67(4):768-776. PubMed ID: 30575958
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
5. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
6. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults.
Chattaris T; Oh G; Gouskova NA; Kim DH; Kiel DP; Berry SD
J Bone Miner Res; 2022 Nov; 37(11):2103-2111. PubMed ID: 36168189
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk.
Luo C; Qin SX; Wang QY; Li YF; Qu XL; Yue C; Hu L; Sheng ZF; Wang XB; Wan XM
J Endocrinol Invest; 2023 Feb; 46(2):367-379. PubMed ID: 36044169
[TBL] [Abstract][Full Text] [Related]
10. Denosumab versus zoledronic acid in elderly patients after hip fracture.
Kim SJ; Kim JW; Lee DW
J Orthop Surg (Hong Kong); 2022; 30(3):10225536221147082. PubMed ID: 36541833
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
[TBL] [Abstract][Full Text] [Related]
14. Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.
Choi NK; Solomon DH; Tsacogianis TN; Landon JE; Song HJ; Kim SC
J Bone Miner Res; 2017 Mar; 32(3):611-617. PubMed ID: 27736041
[TBL] [Abstract][Full Text] [Related]
15. Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.
Lee H; Jin Y; Roh M; Tsacogianis TN; Park S; Choi NK; Kim SC
Drugs Aging; 2020 Apr; 37(4):311-320. PubMed ID: 32026309
[TBL] [Abstract][Full Text] [Related]
16. Polypharmacy in Osteoporosis Treatment.
McConnell M; Shieh A
Clin Geriatr Med; 2022 Nov; 38(4):715-726. PubMed ID: 36210087
[TBL] [Abstract][Full Text] [Related]
17. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis.
Sheedy KC; Camara MI; Camacho PM
Endocr Pract; 2015 Mar; 21(3):275-9. PubMed ID: 25370317
[TBL] [Abstract][Full Text] [Related]
19. Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
McGrath LJ; Spangler L; Curtis JR; Ehrenstein V; Sørensen HT; Saul B; Levintow SN; Reams D; Bradbury BD; Brookhart MA
Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):854-863. PubMed ID: 32537883
[TBL] [Abstract][Full Text] [Related]
20. Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study.
D'Silva KM; Cromer SJ; Yu EW; Fischer M; Kim SC
J Bone Miner Res; 2021 Jan; 36(1):52-60. PubMed ID: 33137852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
